|
1
|
Shonka DC Jr, Ho A, Chintakuntlawar AV,
Geiger JL, Park JC, Seetharamu N, Jasim S, Abdelhamid Ahmed AH,
Bible KC, Brose MS, et al: American Head and Neck Society Endocrine
Surgery Section and International Thyroid Oncology Group consensus
statement on mutational testing in thyroid cancer: Defining
advanced thyroid cancer and its targeted treatment. Head Neck.
44:1277–1300. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo Y: Therapy of head and neck cancer in
China: Introduction to the special issue. Head Neck. 44:2007–2008.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lahtinen S, Nurkkala J, Hannula S, Ohtonen
P, Koivunen P and Liisanantti JH: Perioperative risk factors for
one-year mortality in patients with free-flap reconstruction due to
cancer of the head and neck. J Oral Maxillofac Surg.
79:1384.e1–1384.e5. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marziliano A, Teckie S and Diefenbach MA:
Alcohol-related head and neck cancer: Summary of the literature.
Head Neck. 42:732–738. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ward G, Mehta V and Moore M: Morbidity,
mortality and cost from HPV-related oropharyngeal cancer: Impact of
2-, 4- and 9-valent vaccines. Hum Vaccin Immunother. 12:1343–1347.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mehanna H, Paleri V, West CM and Nutting
C: Head and neck cancer-Part 1: Epidemiology, presentation, and
prevention. BMJ. 341:c46842010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ravikumar S, Casellas NJ, Shah S and Rieth
K: Geographic disparities in head and neck cancer survival in
Upstate New York 2011–2019. Head Neck. 44:472–482. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andisheh-Tadbir A, Mehrabani D and Heydari
ST: Epidemiology of squamous cell carcinoma of the oral cavity in
Iran. J Craniofac Surg. 19:1699–1702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shehan JN, Alwani T, LeClair J, Mahoney
TF, Agarwal P, Chaudhry ST, Wang JJ, Noordzij JP, Tracy LF, Edwards
HA, et al: Social determinants of health and treatment decisions in
head and neck cancer. Head Neck. 44:372–381. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee T, Cho J, Baek CH, Son YI, Jeong HS,
Chung MK, Hong SD, Ahn YC, Oh DR, Noh JM, et al: Prevalence of NUT
carcinoma in head and neck: Analysis of 362 cases with literature
review. Head Neck. 42:924–938. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang TH, Xirasagar S, Cheng YF, Wu CS, Kao
YW, Shia BC and Lin HC: Association between pioglitazone use and
head and neck cancer: Population-based case-control study. Head
Neck. 42:653–659. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ling Z, Cheng B and Tao X:
Epithelial-to-mesenchymal transition in oral squamous cell
carcinoma: Challenges and opportunities. Int J Cancer.
148:1548–1561. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cramer JD, Burtness B, Le QT and Ferris
RL: The changing therapeutic landscape of head and neck cancer. Nat
Rev Clin Oncol. 16:669–683. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saada-Bouzid E, Peyrade F and Guigay J:
Immunotherapy in recurrent and or metastatic squamous cell
carcinoma of the head and neck. Curr Opin Oncol. 31:146–151. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mei Z, Huang J, Qiao B and Lam AK: Immune
checkpoint pathways in immunotherapy for head and neck squamous
cell carcinoma. Int J Oral Sci. 12:162020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Powell SF, Gold KA, Gitau MM, Sumey CJ,
Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD,
et al: Safety and efficacy of Pembrolizumab with chemoradiotherapy
in locally advanced head and neck squamous cell carcinoma: A Phase
IB study. J Clin Oncol. 38:2427–2437. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qureshi HA and Lee SM: Immunotherapy
approaches beyond PD-1 inhibition: The future of cellular therapy
for head and neck squamous cell carcinoma. Curr Treat Options
Oncol. 20:312019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abbott M and Ustoyev Y: Cancer and the
immune system: The history and background of immunotherapy. Semin
Oncol Nurs. 35:1509232019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar
S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, et al: Immune
landscape of Viral- and Carcinogen-driven head and neck cancer.
Immunity. 52:183–199.e9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cramer JD, Burtness B and Ferris RL:
Immunotherapy for head and neck cancer: Recent advances and future
directions. Oral Oncol. 99:1044602019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taberna M, Oliva M and Mesía R:
Cetuximab-Containing combinations in locally advanced and recurrent
or metastatic head and neck squamous cell carcinoma. Front Oncol.
9:3832019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Elbers JBW, Al-Mamgani A, Tesseslaar MET,
van den Brekel MWM, Lange CAH, van der Wal JE, Verheij M, Zuur CL
and de Boer JP: Immuno-radiotherapy with cetuximab and avelumab for
advanced stage head and neck squamous cell carcinoma: Results from
a phase-I trial. Radiother Oncol. 142:79–84. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iovoli AJ, Hermann GM, Ma SJ, Platek AJ,
Farrugia MK, Yau E, Wooten KE, Arshad H, Gupta V, Kuriakose MA, et
al: Association of Nonsteroidal Anti-inflammatory drug use with
survival in patients with squamous cell carcinoma of the head and
neck treated with chemoradiation therapy. JAMA Netw Open.
3:e2071992020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei T, Leisegang M, Xia M, Kiyotani K, Li
N, Zeng C, Deng C, Jiang J, Harada M, Agrawal N, et al: Generation
of neoantigen-specific T cells for adoptive cell transfer for
treating head and neck squamous cell carcinoma. Oncoimmunology.
10:19297262021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wilson HL, D'Agostino RB Jr, Meegalla N,
Petro R, Commander S, Topaloglu U, Zhang W and Porosnicu M: The
prognostic and therapeutic value of the mutational profile of blood
and tumor tissue in head and neck squamous cell carcinoma.
Oncologist. 26:e279–e89. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cohen N, Fedewa S and Chen AY:
Epidemiology and demographics of the head and neck cancer
population. Oral Maxillofac Surg Clin North Am. 30:381–395. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nooreldeen R and Bach H: Current and
future development in lung cancer diagnosis. Int J Mol Sci.
22:86612021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hommel DJ, Brown ML and Kinzie JJ:
Response to radiotherapy of head and neck tumors in AIDS patients.
Am J Surg. 154:443–446. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wilson RE: Surgical oncology. Cancer. 54
(Suppl 11):S2595–S2598. 1984. View Article : Google Scholar
|
|
30
|
Pagedar NA, Kendell N, Christensen AJ,
Thomsen TA, Gist M and Seaman AT: Head and neck cancer survivorship
from the patient perspective. Head Neck. 42:2431–2439. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vincent AG, Wang W, Shokri T and Ducic Y:
Treatment of oligometastatic disease in squamous cell carcinoma of
the head and neck. Laryngoscope. 131:E1476–E1480. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Carron J, Torricelli C, Silva JK, Queiroz
GSR, Ortega MM, Lima CSP and Lourenço GJ: microRNAs deregulation in
head and neck squamous cell carcinoma. Head Neck. 43:645–667. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Philips R, Han C, Swendseid B, Curry J,
Argiris A, Luginbuhl A and Johnson J: Preoperative immunotherapy in
the multidisciplinary management of oral cavity cancer. Front
Oncol. 11:6820752021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Voortman J: Chemoradiotherapy plus a SMAC
mimetic for locally advanced squamous cell carcinoma of the head
and neck. Lancet Oncol. 21:1126–1128. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Botticelli A, Cirillo A, Strigari L,
Valentini F, Cerbelli B, Scagnoli S, Cerbelli E, Zizzari IG, Rocca
CD, D'Amati G, et al: Anti-PD-1 and Anti-PD-L1 in head and neck
cancer: A network meta-analysis. Front Immunol. 12:7050962021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Deschuymer S, Nevens D, Duprez F, Daisne
JF, Dok R, Laenen A, Voordeckers M, De Neve W and Nuyts S:
Randomized clinical trial on reduction of radiotherapy dose to the
elective neck in head and neck squamous cell carcinoma; update of
the long-term tumor outcome. Radiother Oncol. 143:24–29. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Irfan M, Delgado RZR and Frias-Lopez J:
The oral microbiome and cancer. Front Immunol. 11:5910882020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang SH and O'Sullivan B: Overview of the
8th Edition TNM classification for head and neck cancer. Curr Treat
Options Oncol. 18:402017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou K, Li Y, Liao W, Zhang M, Bai L and
Li Q: Pembrolizumab alone or with chemotherapy for squamous cell
carcinoma of the head and neck: A cost-effectiveness analysis from
Chinese perspective. Oral Oncol. 107:1047542020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kreimer AR, Clifford GM, Boyle P and
Franceschi S: Human papillomavirus types in head and neck squamous
cell carcinomas worldwide: A systematic review. Cancer Epidemiol
Biomarkers Prev. 14:467–475. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zilberg C, Lee MW, Kraitsek S, Ashford B,
Ranson M, Shannon K, Iyer NG, Ch'ng S, Low TH, Palme C, et al: Is
high-risk cutaneous squamous cell carcinoma of the head and neck a
suitable candidate for current targeted therapies? J Clin Pathol.
73:17–22. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang L, Yang L, Han S, Zhu J, Li Y, Wang
Z, Fan YH, Lin E, Zhang R, Sahoo N, et al: Patterns of protein
expression in human head and neck cancer cell lines differ after
proton vs photon radiotherapy. Head Neck. 42:289–301. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Akali NR, Buggaveeti R, Sukumaran SV,
Balasubramanian D, Iyer S and Thankappan K: Prior chemoradiotherapy
and pathological perineural invasion predict the survival outcomes
of salvage surgery in head and neck squamous cell carcinoma. Head
Neck. 43:874–883. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ostuni R, Kratochvill F, Murray PJ and
Natoli G: Macrophages and cancer: From mechanisms to therapeutic
implications. Trends Immunol. 36:229–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ottria L, Candotto V, Cura F, Baggi L,
Arcuri C, Nardone M, Gaudio RM, Gatto R, Spadari F and Carinci F:
HPV acting on E-cadherin, p53 and p16: Literature review. J Biol
Regul Homeost Agents. 32 (2 Suppl 1):S73–S79. 2018.PubMed/NCBI
|
|
46
|
Gau M, Karabajakian A, Reverdy T,
Neidhardt EM and Fayette J: Induction chemotherapy in head and neck
cancers: Results and controversies. Oral Oncol. 95:164–169. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang J, Zhong X, Jiang H, Jiang H, Xie T,
Tian Y, Li R, Wang B, Zhang J and Yuan Y: Comprehensive
characterization of the tumor microenvironment for assessing
immunotherapy outcome in patients with head and neck squamous cell
carcinoma. Aging (Albany NY). 12:22509–22526. 2020.PubMed/NCBI
|
|
48
|
Jeans C, Brown B, Ward EC, Vertigan AE,
Pigott AE, Nixon JL and Wratten C: Comparing the prevalence,
location, and severity of head and neck lymphedema after
postoperative radiotherapy for oral cavity cancers and definitive
chemoradiotherapy for oropharyngeal, laryngeal, and hypopharyngeal
cancers. Head Neck. 42:3364–3374. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miyauchi S, Kim SS, Pang J, Gold KA,
Gutkind JS, Califano JA, Mell LK, Cohen EEW and Sharabi AB: Immune
modulation of head and neck squamous cell carcinoma and the tumor
microenvironment by conventional therapeutics. Clin Cancer Res.
25:4211–4223. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim DY, Wu HG, Kim JH, Lee JH, Ahn SH,
Chung EJ, Eom KY, Jung YH, Jeong WJ, Kwon TK, et al: Radiotherapy
versus surgery in early-stage HPV-positive oropharyngeal cancer.
Cancer Res Treat. 54:406–416. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Łasińska I, Kolenda T, Teresiak A,
Lamperska KM, Galus Ł and Mackiewicz J: Immunotherapy in patients
with recurrent and metastatic squamous cell carcinoma of the head
and neck. Anticancer Agents Med Chem. 19:290–303. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tovar JM, Bazaldua OV, Vargas L and Reile
E: Human papillomavirus, cervical cancer, and the vaccines.
Postgrad Med. 120:79–84. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Solomon B, Young RJ and Rischin D: Head
and neck squamous cell carcinoma: Genomics and emerging biomarkers
for immunomodulatory cancer treatments. Semin Cancer Biol.
52:228–240. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
de Ridder M, de Veij Mestdagh PD, Elbers
JBW, Navran A, Zuur CL, Smeele LE and Al-Mamgani A: Disease course
after the first recurrence of head and neck squamous cell carcinoma
following (chemo)radiation. Eur Arch Otorhinolaryngol. 277:261–268.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Singh P, Bennett B, Bailey T,
Taylor-Stokes G, Rajkovic I, Contente M, Curtis S and Curtis C:
Real-world study of the impact of recurrent/metastatic squamous
cell carcinoma of the head and neck (R/M SCCHN) on quality of life
and productivity in Europe. BMC Cancer. 21:8542021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ferris RL, Licitra L, Fayette J, Even C,
Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF,
Haddad R, et al: Nivolumab in patients with recurrent or metastatic
squamous cell carcinoma of the head and neck: Efficacy and safety
in CheckMate 141 by prior cetuximab use. Clin Cancer Res.
25:5221–5230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Billard-Sandu C, Tao YG, Sablin MP,
Dumitrescu G, Billard D and Deutsch E: CDK4/6 inhibitors in
P16/HPV16-negative squamous cell carcinoma of the head and neck.
Eur Arch Otorhinolaryngol. 277:1273–1280. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Paget-Bailly S, Cyr D and Luce D:
Occupational exposures and cancer of the larynx-systematic review
and meta-analysis. J Occup Environ Med. 54:71–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yousefi H, Lak E, Mohammadi MJ and
Shahriyari HA: Carcinogenic risk assessment among children and
adult due to exposure to toxic air pollutants. Environ Sci Pollut
Res Int. 29:23015–23025. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dok R, Bamps M, Glorieux M, Zhao P,
Sablina A and Nuyts S: Radiosensitization approaches for
HPV-positive and HPV-negative head and neck squamous carcinomas.
Int J Cancer. 146:1075–1085. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Guo F, Chang M, Scholl M, McKinnon B and
Berenson AB: Trends in oropharyngeal cancer incidence among adult
men and women in the United States from 2001 to 2018. Front Oncol.
12:9265552022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zolkind P, Lee JJ, Jackson RS, Pipkorn P
and Massa ST: Untreated head and neck cancer: Natural history and
associated factors. Head Neck. 43:89–97. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Valero C, Ganly I and Shah JP: Head and
neck paragangliomas: 30-year experience. Head Neck. 42:2486–2495.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pike LRG, Royce TJ, Mahal AR, Kim DW,
Hwang WL, Mahal BA and Sanford NN: Outcomes of HPV-Associated
squamous cell carcinoma of the head and neck: Impact of race and
socioeconomic status. J Natl Compr Canc Netw. 18:177–184.
2020.PubMed/NCBI
|
|
65
|
Lach FP, Singh S, Rickman KA, Ruiz PD,
Noonan RJ, Hymes KB, DeLacure MD, Kennedy JA, Chandrasekharappa SC
and Smogorzewska A: Esophageal cancer as initial presentation of
Fanconi anemia in patients with a hypomorphic FANCA variant. Cold
Spring Harb Mol Case Stud. 6:a0055952020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Saksø M, Mortensen LS, Primdahl H,
Johansen J, Kallehauge J, Hansen CR and Overgaard J: Influence of
FAZA PET hypoxia and HPV-status for the outcome of head and neck
squamous cell carcinoma (HNSCC) treated with radiotherapy:
Long-term results from the DAHANCA 24 trial (NCT01017224).
Radiother Oncol. 151:126–133. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhou C and Parsons JL: The radiobiology of
HPV-positive and HPV-negative head and neck squamous cell
carcinoma. Expert Rev Mol Med. 22:e32020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Larsen K, Rydz E and Peters CE:
Inequalities in environmental cancer risk and carcinogen exposures:
A scoping review. Int J Environ Res Public Health. 20:57182023.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Fishbein A, Hammock BD, Serhan CN and
Panigrahy D: Carcinogenesis: Failure of resolution of inflammation?
Pharmacol Ther. 218:1076702021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Boffetta P, Hecht S, Gray N, Gupta P and
Straif K: Smokeless tobacco and cancer. Lancet Oncol. 9:667–675.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Hecht SS: Tobacco carcinogens, their
biomarkers and tobacco-induced cancer. Nat Rev Cancer. 3:733–744.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Rumfield CS, Schlom J and Jochems C:
Combination therapies for HPV-associated malignancies. J Clin Cell
Immunol. 12:6082021.
|
|
73
|
Huang C and Zhan L: Network pharmacology
identifies therapeutic targets and the mechanisms of glutathione
action in ferroptosis occurring in oral cancer. Front Pharmacol.
13:8515402022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zandberg DP, Bhargava R, Badin S and
Cullen KJ: The role of human papillomavirus in nongenital cancers.
CA Cancer J Clin. 63:57–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wang J, Sun H, Zeng Q, Guo XJ, Wang H, Liu
HH and Dong ZY: HPV-positive status associated with inflamed immune
microenvironment and improved response to anti-PD-1 therapy in head
and neck squamous cell carcinoma. Sci Rep. 9:134042019. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Beddok A, Vela A, Calugaru V, Tessonnier
T, Kubes J, Dutheil P, Gerard A, Vidal M, Goudjil F, Florescu C, et
al: Proton therapy for head and neck squamous cell carcinomas: A
review of the physical and clinical challenges. Radiother Oncol.
147:30–39. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ding L, Ren J, Zhang D, Li Y, Huang X, Hu
Q, Wang H, Song Y, Ni Y and Hou Y: A novel stromal lncRNA signature
reprograms fibroblasts to promote the growth of oral squamous cell
carcinoma via LncRNA-CAF/interleukin-33. Carcinogenesis.
39:397–406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Johnson DE, Burtness B, Leemans CR, Lui
VWY, Bauman JE and Grandis JR: Head and neck squamous cell
carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Nathan CA, Khandelwal AR, Wolf GT, Rodrigo
JP, Mäkitie AA, Saba NF, Forastiere AA, Bradford CR and Ferlito A:
TP53 mutations in head and neck cancer. Mol Carcinog. 61:385–391.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Renken S, Nakajima T, Magalhaes I,
Mattsson J, Lundqvist A, Arnér ESJ, Kiessling R and Wickström SL:
Targeting of Nrf2 improves antitumoral responses by human NK cells,
TIL and CAR T cells during oxidative stress. J Immunother Cancer.
10:e0044582022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Chen SMY, Krinsky AL, Woolaver RA, Wang X,
Chen Z and Wang JH: Tumor immune microenvironment in head and neck
cancers. Mol Carcinog. 59:766–774. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Brand M, Laban S, Theodoraki MN, Doescher
J, Hoffmann TK, Schuler PJ and Brunner C: Characterization and
differentiation of the tumor microenvironment (TME) of orthotopic
and subcutaneously grown head and neck squamous cell carcinoma
(HNSCC) in immunocompetent mice. Int J Mol Sci. 22:2472020.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wang G, Zhang M, Cheng M, Wang X, Li K,
Chen J, Chen Z, Chen S, Chen J, Xiong G, et al: Tumor
microenvironment in head and neck squamous cell carcinoma:
Functions and regulatory mechanisms. Cancer Lett. 507:55–69. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Al-Assaf H, Erler D, Karam I, Lee JW,
Higgins K, Enepekides D, Zhang L, Eskander A and Poon I:
Stereotactic body radiotherapy for medically unfit patients with
cancers to the head and neck. Head Neck. 42:2050–2057. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Evrard D, Szturz P, Tijeras-Raballand A,
Astorgues-Xerri L, Abitbol C, Paradis V, Raymond E, Albert S, Barry
B and Faivre S: Macrophages in the microenvironment of head and
neck cancer: Potential targets for cancer therapy. Oral Oncol.
88:29–38. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Vengaloor Thomas T, Packianathan S, Bhanat
E, Albert A, Abraham A, Gordy X, Kanakamedala M, Mehta D and
Vijayakumar S: Oligometastatic head and neck cancer: Comprehensive
review. Head Neck. 42:2194–2201. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Raudenska M, Balvan J and Masarik M: Cell
death in head and neck cancer pathogenesis and treatment. Cell
Death Dis. 12:1922021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK,
Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, et al:
Identification and validation of novel microenvironment-based
immune molecular subgroups of head and neck squamous cell
carcinoma: Implications for immunotherapy. Ann Oncol. 30:68–75.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wu P, Yuan G, Lu Z, Yang S, Zhu H, Zhou R,
Wilson Wai SH, Cai J and Raymond King YT: Extracranial/intracranial
vascular bypass to control carotid artery blowout in postirradiated
nasopharyngeal carcinoma patients. Lin Chung Er Bi Yan Hou Tou Jing
Wai Ke Za Zhi. 35:448–452. 2021.(In Chinese). PubMed/NCBI
|
|
90
|
Pittet MJ, Michielin O and Migliorini D:
Clinical relevance of tumour-associated macrophages. Nat Rev Clin
Oncol. 19:402–421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
León X, Pujals G, Bulboa C, García J,
López M and Quer M: Head and neck squamous cell carcinoma in cigar
smokers. Distinctive epidemiological and prognostic
characteristics. Acta Otorrinolaringol Esp (Engl Ed). 72:222–229.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhang Z, Wu B, Peng G, Xiao G, Huang J,
Ding Q, Yang C, Xiong X, Ma H, Shi L, et al: Neoadjuvant
chemoimmunotherapy for the treatment of locally advanced head and
neck squamous cell carcinoma: A Single-Arm phase 2 clinical trial.
Clin Cancer Res. 28:3268–3276. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Madhukar G and Subbarao N: Current and
future therapeutic targets: A review on treating head and neck
squamous cell carcinoma. Curr Cancer Drug Targets. 21:386–400.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Machiels JP, Tao Y, Burtness B, Tahara M,
Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K,
et al: Pembrolizumab given concomitantly with chemoradiation and as
maintenance therapy for locally advanced head and neck squamous
cell carcinoma: KEYNOTE-412. Future Oncol. 16:1235–1243. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Cohen EEW, Soulières D, Le Tourneau C,
Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R,
et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab
for recurrent or metastatic head-and-neck squamous cell carcinoma
(KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet.
393:156–167. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Hughes BGM, Munoz-Couselo E, Mortier L,
Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J,
Arance A, Grange F, et al: Pembrolizumab for locally advanced and
recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629
Study): An open-label, nonrandomized, multicenter, phase 2 trial.
Ann Oncol. 32:1276–1285. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wu J, Yuan Y and Tao XF: Targeted
molecular imaging of head and neck squamous cell carcinoma: A
window into precision medicine. Chin Med J (Engl). 133:1325–1336.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Rangabashyam MS, Lee SY, Tan SY, Mueller
S, Sultana R, Ho J, Skanthakumar T, Tan NC, Tan HK, Soo KC and Iyer
NG: Adherence of head and neck squamous cell carcinoma patients to
tumor board recommendations. Cancer Med. 9:5124–5133. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Huang JJ, Geduldig JE, Jacobs EB, Tai TYT,
Ahmad S, Chadha N, Buxton DF, Vinod K, Wirostko BM, Kang JH, et al:
Head and neck region dermatological Ultraviolet-Related cancers are
associated with exfoliation syndrome in a clinic-based population.
Ophthalmol Glaucoma. 5:663–671. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Liang B, Tao Y and Wang T: Profiles of
immune cell infiltration in head and neck squamous carcinoma.
Biosci Rep. 40:BSR201927242020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy
versus chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Kochanek SJ, Close DA, Camarco DP and
Johnston PA: Maximizing the value of cancer drug screening in
multicellular tumor spheroid cultures: A case study in five head
and neck squamous cell carcinoma cell lines. SLAS Discov.
25:329–349. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Kang KH, Lebow ES, Niemierko A, Bussière
MR, Dewyer NA, Daly J, McKenna MJ, Lee DJ, Loeffler JS, Busse PM
and Shih HA: Proton therapy for head and neck paragangliomas: A
single institutional experience. Head Neck. 42:670–677. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Guidi A, Codecà C and Ferrari D:
Chemotherapy and immunotherapy for recurrent and metastatic head
and neck cancer: A systematic review. Med Oncol. 35:372018.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Ferris RL, Moskovitz J, Kunning S, Ruffin
AT, Reeder C, Ohr J, Gooding WE, Kim S, Karlovits BJ, Vignali DAA,
et al: Phase I Trial of cetuximab, radiotherapy, and ipilimumab in
locally advanced head and neck cancer. Clin Cancer Res.
28:1335–1344. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Faur CI, Falamas A, Chirila M, Roman RC,
Rotaru H, Moldovan MA, Albu S, Baciut M, Robu I and Hedesiu M:
Raman spectroscopy in oral cavity and oropharyngeal cancer: A
systematic review. Int J Oral Maxillofac Surg. 51:1373–1381. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Kao HF and Lou PJ: Immune checkpoint
inhibitors for head and neck squamous cell carcinoma: Current
landscape and future directions. Head Neck. 41 (Suppl 1):4–18.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Tao L, Zhou L, Zhang M, Wu H, Li X, Chen
X, Li C, Shi Y, Cheng L and Lin H: Postoperative prognostic risk
factors and treatment strategies for patients with T3-T4
hypopharyngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou
Jing Wai Ke Za Zhi. 35:400–404. 2021.(In Chinese). PubMed/NCBI
|
|
109
|
Okano S, Homma A, Kiyota N, Tahara M,
Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, et al:
Induction chemotherapy in locally advanced squamous cell carcinoma
of the head and neck. Jpn J Clin Oncol. 51:173–179. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang L, Ma Q, Yao R and Liu J: Current
status and development of anti-PD-1/PD-L1 immunotherapy for lung
cancer. Int Immunopharmacol. 79:1060882020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Mingo KM, Derakhshan A, Abdullah N, Chute
DJ, Koyfman SA, Lamarre ED and Burkey BB: Characteristics and
outcomes in head and neck sarcomatoid squamous cell carcinoma: The
cleveland clinic experience. Ann Otol Rhinol Laryngol. 130:818–824.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wei C, Yang C, Wang S, Shi D, Zhang C, Lin
X, Liu Q, Dou R and Xiong B: Crosstalk between cancer cells and
tumor associated macrophages is required for mesenchymal
circulating tumor cell-mediated colorectal cancer metastasis. Mol
Cancer. 18:642019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu XC, Ma SR, Shi S, Zhao YF and Jia J:
Prognostic significance of lymph node ratio in patients with
squamous cell carcinoma of the floor of the mouth. Int J Oral
Maxillofac Surg. 51:307–313. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Varra V, Smile TD, Geiger JL and Koyfman
SA: Recent and emerging therapies for cutaneous squamous cell
carcinomas of the head and neck. Curr Treat Options Oncol.
21:372020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Highland J, Aylward A, Do O, Monroe M and
Buchmann L: Trust in physicians among patients with head and neck
cancer before and after treatment. Head Neck. 43:2580–2588. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Tam S, Yao C, Amit M, Gajera M, Luo X,
Treistman R, Khanna A, Aashiq M, Nagarajan P, Bell D, et al:
Association of immunosuppression with outcomes of patients with
cutaneous squamous cell carcinoma of the head and neck. JAMA
Otolaryngol Head Neck Surg. 146:128–135. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wang W, Green M, Choi JE, Gijon M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al:
CD8+ T cells regulate tumour ferroptosis during cancer
immunotherapy. Nature. 569:270–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Valdes M, Villeda J, Mithoowani H, Pitre T
and Chasen M: Inflammatory markers as prognostic factors of
recurrence in advanced-stage squamous cell carcinoma of the head
and neck. Curr Oncol. 27:135–141. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Cristina V, Herrera-Gómez RG, Szturz P,
Espeli V and Siano M: Immunotherapies and future combination
strategies for head and neck squamous cell carcinoma. Int J Mol
Sci. 20:53992019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Chatterjee S, Kiyota N, Vaish R, Sharma A,
Tahara M, Noronha V, Prabhash K and D'Cruz A: Weekly versus
3-weekly cisplatin along with radiotherapy for locoregionally
advanced non-nasopharyngeal head and neck cancers: Is the equipoise
in literature addressed yet? Head Neck. 45:1594–1603. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang Y, Dong L, Bi Q, Li X, Wu D, Ge X,
Zhang X, Fu J, Zhang C, Wang C and Li S: Investigation of the
efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating
head and neck squamous cell carcinoma in mice. Target Oncol.
5:237–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Ham JC, van Meerten E, Fiets WE, Beerepoot
LV, Jeurissen FJF, Slingerland M, Jonker MA, Husson O, van der
Graaf WTA and van Herpen CML: Methotrexate plus or minus cetuximab
as first-line treatment in a recurrent or metastatic (R/M) squamous
cell carcinoma population of the head and neck (SCCHN), unfit for
cisplatin combination treatment, a phase Ib-randomized phase II
study Commence. Head Neck. 42:828–838. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Kaboli PJ, Zhang L, Xiang S, Shen J, Li M,
Zhao Y, Wu X, Zhao Q, Zhang H, Lin L, et al: Molecular markers of
regulatory T cells in cancer immunotherapy with special focus on
acute myeloid leukemia (AML)-a systematic review. Curr Med Chem.
27:4673–4698. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Jia T, Ming SX, Cao QQ and Xu FL: Combined
treatment with acetazolamide and cisplatin enhances the
chemosensitivity of human head and neck squamous cell carcinoma
TU868 cells. Arch Oral Biol. 119:1049052020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Masarwy R, Kampel L, Horowitz G, Gutfeld O
and Muhanna N: Neoadjuvant PD-1/PD-L1 inhibitors for resectable
head and neck cancer: A systematic review and meta-analysis. JAMA
Otolaryngol Head Neck Surg. 147:871–878. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Kimura H, Hamauchi S, Kawai S, Onozawa Y,
Yasui H, Yamashita A, Ogawa H, Onoe T, Kamijo T, Iida Y, et al:
Pretreatment predictive factors for feasibility of oral intake in
adjuvant concurrent chemoradiotherapy for patients with locally
advanced squamous cell carcinoma of the head and neck. Int J Clin
Oncol. 25:258–266. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Rotman J, den Otter LAS, Bleeker MCG,
Samuels SS, Heeren AM, Roemer MGM, Kenter GG, Zijlmans HJMAA, van
Trommel NE, de Gruijl TD and Jordanova ES: PD-L1 and PD-L2
expression in cervical cancer: Regulation and biomarker potential.
Front Immunol. 11:5968252020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Brody RM, Albergotti WG, Shimunov D,
Nicolli E, Patel UA, Harris BN and Bur AM: Changes in head and neck
oncologic practice during the COVID-19 pandemic. Head Neck.
42:1448–1453. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Jin Y and Qin X: Co-expression
network-based identification of biomarkers correlated with the
lymph node metastasis of patients with head and neck squamous cell
carcinoma. Biosci Rep. 40:BSR201940672020. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Addeo A, Friedlaender A, Banna GL and
Weiss GJ: TMB or not TMB as a biomarker: That is the question. Crit
Rev Oncol Hematol. 163:1033742021. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Park R and Park JC: Current landscape of
immunotherapy trials in locally advanced and high-risk head and
neck cancer. Immunotherapy. 13:931–940. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Alsahafi E, Begg K, Amelio I, Raulf N,
Lucarelli P, Sauter T and Tavassoli M: Clinical update on head and
neck cancer: Molecular biology and ongoing challenges. Cell Death
Dis. 10:5402019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Maio M, Blank C, Necchi A, Di Giacomo AM,
Ibrahim R, Lahn M, Fox BA, Bell RB, Tortora G and Eggermont AMM:
Neoadjuvant immunotherapy is reshaping cancer management across
multiple tumour types: The future is now! Eur J Cancer.
152:155–164. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Hopkins-Rossabi T, Armeson KE, Zecker SG
and Martin-Harris B: Respiratory-swallow coordination and
swallowing impairment in head and neck cancer. Head Neck.
43:1398–1408. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Ferrari M, Taboni S, Carobbio ALC,
Emanuelli E, Maroldi R, Bossi P and Nicolai P: Sinonasal squamous
cell carcinoma, a narrative reappraisal of the current evidence.
Cancers (Basel). 13:28352021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Long J, Wang D, Yang X, Wang A, Lin Y,
Zheng M, Zhang H, Sang X, Wang H, Hu K and Zhao H: Identification
of NOTCH4 mutation as a response biomarker for immune checkpoint
inhibitor therapy. BMC Med. 19:1542021. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Kabzinski J, Maczynska M and Majsterek I:
MicroRNA as a novel biomarker in the diagnosis of head and neck
cancer. Biomolecules. 11:8442021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Suzuki A, Kashiwagi N, Doi H, Ishii K, Doi
K, Kitano M, Kozuka T, Hyodo T, Tsurusaki M, Yagyu Y and Nakanishi
K: Patterns of bone metastases from head and neck squamous cell
carcinoma. Auris Nasus Larynx. 47:262–267. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Yu J, Smith J, Marwah R and Edkins O:
Return to work in patients with head and neck cancer: Systematic
review and meta-analysis. Head Neck. 44:2904–2924. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Patel JJ, Levy DA, Nguyen SA, Knochelmann
HM and Day TA: Impact of PD-L1 expression and human papillomavirus
status in anti-PD1/PDL1 immunotherapy for head and neck squamous
cell carcinoma-Systematic review and meta-analysis. Head Neck.
42:774–786. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
de Oliveira TB, Marta GN, de Castro Junior
G and Kowalski LP: Induction chemotherapy for advanced oral cavity
cancer. Curr Oncol Rep. 23:1292021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Campo F, Zocchi J, Moretto S, Mazzola F,
Petruzzi G, Donà MG, Benevolo M, Iocca O, De Virgilio A, Pichi B,
et al: Cell-free human papillomavirus-DNA for monitoring treatment
response of head and neck squamous cell carcinoma: Systematic
review and meta-analysis. Laryngoscope. 132:560–568. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Lecocq M, Poncin A and Sautois B:
Immunotherapy for head and neck squamous cell carcinoma. Rev Med
Liege. 76:398–402. 2021.(In French). PubMed/NCBI
|
|
146
|
van de Goor R, van Hooren MRA, Henatsch D,
Kremer B and Kross KW: Detecting head and neck squamous carcinoma
using a portable handheld electronic nose. Head Neck. 42:2555–2559.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Yan F, Lao WP, Nguyen SA, Sharma AK and
Day TA: Elective neck dissection in salivary gland malignancies:
Systematic review and meta-analysis. Head Neck. 44:505–517. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Qiang W, Dai Y, Xing X and Sun X:
Identification and validation of a prognostic signature and
combination drug therapy for immunotherapy of head and neck
squamous cell carcinoma. Comput Struct Biotechnol J. 19:1263–1276.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Wang Z, Goto Y, Allevato MM, Wu VH,
Saddawi-Konefka R, Gilardi M, Alvarado D, Yung BS, O'Farrell A,
Molinolo AA, et al: Disruption of the HER3-PI3K-mTOR oncogenic
signaling axis and PD-1 blockade as a multimodal precision
immunotherapy in head and neck cancer. Nat Commun. 12:23832021.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Eckel HE and Bradley PJ: Treatment options
for hypopharyngeal cancer. Adv Otorhinolaryngol. 83:47–53.
2019.PubMed/NCBI
|
|
151
|
Vasiliadou I, Breik O, Baker H, Leslie I,
Sim VR, Hegarty G, Michaelidou A, Nathan K, Hartley A, Good J, et
al: Safety and treatment outcomes of nivolumab for the treatment of
recurrent or metastatic head and neck squamous cell carcinoma:
Retrospective multicenter cohort study. Cancers (Basel).
13:14132021. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Leidner R, Crittenden M, Young K, Xiao H,
Wu Y, Couey MA, Patel AA, Cheng AC, Watters AL, Bifulco C, et al:
Neoadjuvant immunoradiotherapy results in high rate of complete
pathological response and clinical to pathological downstaging in
locally advanced head and neck squamous cell carcinoma. J
Immunother Cancer. 9:e0024852021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Dua D, Kelly C, Kovarik J and Iqbal MS:
The role of combining immunotherapy with primary
(Chemo)radiotherapy in curative treatment settings of the head and
neck cancer. Asia Pac J Clin Oncol. 18:e3–e10. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Van Wigcheren GF, De Haas N, Mulder TA,
Horrevorts SK, Bloemendal M, Hins-Debree S, Mao Y, Kiessling R, van
Herpen CML, Flórez-Grau G, et al: Cisplatin inhibits frequency and
suppressive activity of monocytic myeloid-derived suppressor cells
in cancer patients. Oncoimmunology. 10:19355572021. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Semrau S, Gostian AO, Traxdorf M, Eckstein
M, Rutzner S, von der Grün J, Illmer T, Hautmann M, Klautke G,
Laban S, et al: Implementation of double immune checkpoint blockade
increases response rate to induction chemotherapy in head and neck
cancer. Cancers (Basel). 13:19592021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Li X, Fang Q, Du W, Zhang X, Dai L and
Qiao Y: Induction chemotherapy combined with immunotherapy in
locally advanced head and neck squamous cell carcinoma. BMC Cancer.
21:6222021. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Niccoli Asabella A, Nappi AG, Trani O,
Sardaro A and Rubini G: Heterogeneous response to immunotherapy in
a patient with tonsillar squamous cell carcinoma assessed by
18F-FDG PET/CT. Diagnostics (Basel). 11:3482021.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Rothschild U, Muller L, Lechner A,
Schlösser HA, Beutner D, Läubli H, Zippelius A and Rothschild SI:
Immunotherapy in head and neck cancer-scientific rationale, current
treatment options and future directions. Swiss Med Wkly.
148:w146252018.PubMed/NCBI
|
|
159
|
Kim MS, Malik NH, Chen H, Poon I, Husain
Z, Eskander A, Boldt G, Louie AV and Karam I: Stereotactic
radiotherapy as planned boost after definitive radiotherapy for
head and neck cancers: Systematic review. Head Neck. 44:770–782.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Shibata H, Saito S and Uppaluri R:
Immunotherapy for head and neck cancer: A paradigm shift from
induction chemotherapy to neoadjuvant immunotherapy. Front Oncol.
11:7274332021. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Koukourakis IM, Giakzidis AG, Kouroupi M,
Giatromanolaki A, Abatzoglou I, Karpouzis A and Koukourakis MI:
Cutaneous squamous-cell carcinoma of the head-neck area refractory
to chemo-radiotherapy: Benefit from anti-PD-1 immunotherapy. BJR
Case Rep. 7:202001702021.PubMed/NCBI
|
|
162
|
Hyytiäinen A, Wahbi W, Väyrynen O,
Saarilahti K, Karihtala P, Salo T and Al-Samadi A: Angiogenesis
inhibitors for head and neck squamous cell carcinoma treatment: Is
there still hope? Front Oncol. 11:6835702021. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Jagadeeshan S, Prasad M, Ortiz-Cuaran S,
Gregoire V, Saintigny P and Elkabets M: Adaptive responses to
monotherapy in head and neck cancer: Interventions for
rationale-based therapeutic combinations. Trends Cancer. 5:365–390.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Yang YM, Hong P, Xu WW, He QY and Li B:
Advances in targeted therapy for esophageal cancer. Signal
Transduct Target Ther. 5:2292020. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Yu S, Wang Y, He P, Shao B, Liu F, Xiang
Z, Yang T, Zeng Y, He T, Ma J, et al: Effective combinations of
immunotherapy and radiotherapy for cancer treatment. Front Oncol.
12:8093042022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Huguet F, Durand B, Atallah S, Prébet C,
Richard S and Baujat B: Combination of radiation
therapy-immunotherapy for head and neck cancers: Promises kept?
Cancer Radiother. 25:811–815. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Biau J and Bourhis J: Combining
immunotherapy and radiotherapy in head and neck squamous cell
cancers: Which perspectives? Curr Opin Oncol. 32:196–202. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Wang HQ, Fu R, Man QW, Yang G, Liu B and
Bu LL: Advances in CAR-T cell therapy in head and neck squamous
cell carcinoma. J Clin Med. 12:21732023. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Kosti P, Opzoomer JW, Larios-Martinez KI,
Henley-Smith R, Scudamore CL, Okesola M, Taher MYM, Davies DM,
Muliaditan T, Larcombe-Young D, et al: Hypoxia-sensing CAR T cells
provide safety and efficacy in treating solid tumors. Cell Rep Med.
2:1002272021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Huang J, Zheng M, Zhang Z, Tang X, Chen Y,
Peng A, Peng X, Tong A and Zhou L: Interleukin-7-loaded oncolytic
adenovirus improves CAR-T cell therapy for glioblastoma. Cancer
Immunol Immunother. 70:2453–2465. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Mei Z, Zhang K, Lam AK, Huang J, Qiu F,
Qiao B and Zhang Y: MUC1 as a target for CAR-T therapy in head and
neck squamous cell carinoma. Cancer Med. 9:640–652. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Vedvyas Y, McCloskey JE, Yang Y, Min IM,
Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, Van Besien K, Gaudet I, et
al: Manufacturing and preclinical validation of CAR T cells
targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep.
9:106342019. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Soldierer M, Bister A, Haist C, Thivakaran
A, Cengiz SC, Sendker S, Bartels N, Thomitzek A, Smorra D, Hejazi
M, et al: Genetic engineering and enrichment of human NK cells for
CAR-enhanced immunotherapy of hematological malignancies. Front
Immunol. 13:8470082022. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Sridhar P and Petrocca F: Regional
delivery of chimeric antigen receptor (CAR) T-cells for cancer
therapy. Cancers (Basel). 9:922017. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Barata A, Hoogland AI, Kommalapati A,
Logue J, Welniak T, Hyland KA, Eisel SL, Small BJ, Jayani RV,
Booth-Jones M, et al: Change in Patients' perceived cognition
following chimeric antigen receptor T-cell therapy for lymphoma.
Transplant Cell Ther. 28:401.e72022. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Wang G, Zhang Z, Zhong K, Wang Z, Yang N,
Tang X, Li H, Lu Q, Wu Z, Yuan B, et al: CXCL11-armed oncolytic
adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram
tumor microenvironment in glioblastoma. Mol Ther. 31:134–153. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Haist C, Poschinski Z, Bister A, Hoffmann
MJ, Grunewald CM, Hamacher A, Kassack M, Wiek C, Scheckenbach K and
Hanenberg H: Engineering a single-chain variable fragment of
cetuximab for CAR T-cell therapy against head and neck squamous
cell carcinomas. Oral Oncol. 129:1058672022. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Plavc G and Strojan P: Combining
radiotherapy and immunotherapy in definitive treatment of head and
neck squamous cell carcinoma: Review of current clinical trials.
Radiol Oncol. 54:377–393. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Botticelli A, Pomati G, Cirillo A, Mammone
G, Ciurluini F, Cerbelli B, Sciattella P, Ralli M, Romeo U, De
Felice F, et al: Weekly chemotherapy as first line treatment in
frail head and neck cancer patients in the immunotherapy era. J
Transl Med. 19:3032021. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Rajendra A, Noronha V, Joshi A, Patil VM,
Menon N and Prabhash K: Palliative chemotherapy in head and neck
cancer: Balancing between beneficial and adverse effects. Expert
Rev Anticancer Ther. 20:17–29. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Choi JS, Sansoni ER, Lovin BD, Lindquist
NR, Phan J, Mayo LL, Ferrarotto R and Su SY: Abscopal effect
following immunotherapy and combined stereotactic body radiation
therapy in recurrent metastatic head and neck squamous cell
carcinoma: A report of two cases and literature review. Ann Otol
Rhinol Laryngol. 129:517–522. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Davern M and Lysaght J: Cooperation
between chemotherapy and immunotherapy in gastroesophageal cancers.
Cancer Lett. 495:89–99. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Zhang W, Yan C, Gao X, Li X, Cao F, Zhao
G, Zhao J, Er P, Zhang T, Chen X, et al: Safety and feasibility of
radiotherapy plus camrelizumab for locally advanced esophageal
squamous cell carcinoma. Oncologist. 26:e1110–e1124. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Altay-Langguth A, Balermpas P, Brandts C,
Balster S, Ghanaati S, Winkelmann R, Burck I, Rödel F, Martin D,
Rödel C and von der Grün J: Re-irradiation with concurrent and
maintenance nivolumab in locally recurrent and inoperable squamous
cell carcinoma of the head and neck: A single-center cohort study.
Clin Transl Radiat Oncol. 28:71–78. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Patel B and Saba NF: Current aspects and
future considerations of EGFR inhibition in locally advanced and
recurrent metastatic squamous cell carcinoma of the head and neck.
Cancers (Basel). 13:35452021. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Leu M, Patzer C, Guhlich M, Possiel J,
Pilavakis Y, Schirmer MA, Rieken S and Dröge LH: Postoperative
radiochemotherapy using modern radiotherapy techniques in elderly
patients with head and neck squamous cell carcinoma: The challenge
of weighing Up benefits and harms of treatment modalities in
clinical practice. Cancers (Basel). 13:33842021. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Fang PQ, Gunther JR, Wu SY, Dabaja BS,
Nastoupil LJ, Ahmed S, Neelapu SS and Pinnix CC: Radiation and CAR
T-cell therapy in lymphoma: Future frontiers and potential
opportunities for synergy. Front Oncol. 11:6486552021. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Wang H, Zhao Q, Zhang Y, Zhang Q, Zheng Z,
Liu S, Liu Z, Meng L, Xin Y and Jiang X: Immunotherapy advances in
locally advanced and recurrent/metastatic head and neck squamous
cell carcinoma and its relationship with human papillomavirus.
Front Immunol. 12:6520542021. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Patin EC, Dillon MT, Nenclares P, Grove L,
Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E,
Baldock H, et al: Harnessing radiotherapy-induced NK-cell activity
by combining DNA damage-response inhibition and immune checkpoint
blockade. J Immunother Cancer. 10:e0043062022. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Hecht M, Eckstein M, Rutzner S, von der
Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB,
Tamaskovics B, et al: Induction chemoimmunotherapy followed by CD8+
immune cell-based patient selection for chemotherapy-free
radioimmunotherapy in locally advanced head and neck cancer. J
Immunother Cancer. 10:e0037472022. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Zeng S, Fu L, Zhou P and Ling H:
Identifying risk factors for the prognosis of head and neck
cutaneous squamous cell carcinoma: A systematic review and
meta-analysis. PLoS One. 15:e02395862020. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Jin WJ, Erbe AK, Schwarz CN, Jaquish AA,
Anderson BR, Sriramaneni RN, Jagodinsky JC, Bates AM, Clark PA, Le
T, et al: Tumor-specific antibody, cetuximab, enhances the in situ
vaccine effect of radiation in immunologically cold head and neck
squamous cell carcinoma. Front Immunol. 11:5911392020. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L
and Liu X: Application of PD-1 blockade in cancer immunotherapy.
Comput Struct Biotechnol J. 17:661–674. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Cohen EEW, Bell RB, Bifulco CB, Burtness
B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL,
et al: The society for immunotherapy of cancer consensus statement
on immunotherapy for the treatment of squamous cell carcinoma of
the head and neck (HNSCC). J Immunother Cancer. 7:1842019.
View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Kordbacheh F and Farah CS: Molecular
pathways and druggable targets in head and neck squamous cell
carcinoma. Cancers (Basel). 13:34532021. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Myers JA and Miller JS: Exploring the NK
cell platform for cancer immunotherapy. Nat Rev Clin Oncol.
18:85–100. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Yokota T, Homma A, Kiyota N, Tahara M,
Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, et al:
Immunotherapy for squamous cell carcinoma of the head and neck. Jpn
J Clin Oncol. 50:1089–1096. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Boros A, Blanchard P, Dade A, Gorphe P,
Breuskin I, Even C, Nguyen F, Deutsch E, Bidault F, Janot F, et al:
Outcomes in N3 head and neck squamous cell carcinoma and role of
upfront neck dissection. Laryngoscope. 131:E846–E850. 2021.
View Article : Google Scholar : PubMed/NCBI
|
